‘Unsavoury’ Practices: Pharma Will Need To Be More Transparent On CME Expenses In India

Faces Audits Under Revised Rules

India’s revised code for marketing practices includes US Sunshine Act-like requirements converging with tax laws and puts the spotlight on continuing medical education initiatives, where pharma will need to display funding/expenditure data on their website. The Pink Sheet talks to experts on the implications and also new requirements on brand reminders and drug samples.

India's revised code for pharma marketing practices outlines guidelines for CME programs • Source: Shutterstock

India’s revised Uniform Code for Pharmaceutical Marketing Practices (UCPMP) has widened disclosure requirements for industry’s interactions with healthcare professionals and laid down a framework for continuing medical education (CME) programs that includes enabling provisions for an audit of these initiatives.

While the conduct of CMEs and continuing professional development (CPD) programs at “foreign locations” has been barred, UCPMP 2024 requires...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from India

More from Asia